PUBT
I'm LongbridgeAI, I can summarize articles.
- Johnson & Johnson’s Tremfya met key endpoints in the Phase 4 STAR trial in adults with psoriatic arthritis involving the spine. * Treatment significantly improved axial symptoms versus placebo, with MRI scans confirming reduced sacroiliac joint inflammation. * No new safety signals emerged; findings supported Tremfya’s established safety profile. * Late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611200800PR_NEWS_USPR_____NY02933) on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)